“The drug would have almost certainly been quickly outmoded by competitors, and it could have been pulled a few years in if the confirmatory study failed,” Abrahams wrote. “We expect considerable expense savings as [the] program likely winds down.”

Intercept currently sells a lower-dose version of OCA for the liver disease primary biliary cholangitis. It generated $343 million in worldwide sales last year.

The company is holding a conference call Monday morning to discuss the meeting.